Biomedical sector B shares rose in the afternoon, as of the time of publication,$LAEKNA-B (02105.HK)$up 27.88%, at 7.89 Hong Kong dollars;$IMMUNEONCO-B (01541.HK)$up 17.91%, at 5.86 Hong Kong dollars;$ASCENTAGE-B (06855.HK)$up 5.74%, at 46.95 Hong Kong dollars.

On the news front, the 2024 medical insurance negotiation is about to enter the negotiation/auction phase. According to Guotou Securities, this medical insurance negotiation has about 41 domestic exclusive innovative drugs (including introductions) that have passed the formal review and are expected to enter drug negotiations: including 28 innovative drugs newly listed between July 1, 2023, and June 30, 2024, and 13 innovative drugs approved for listing before July 1, 2023. The bank believes that the national negotiation is entering a normal stage, and long-term mass production of innovative drugs is expected.

Bocom Intl pointed out that the tenth batch of national drug procurement volume files show that this round of national procurement has the highest historical threshold, the highest proportion of injections, and is expected to be unusually intense. However, for most prescription drug companies, there are relatively few major varieties involved, so the impact may be limited. It is recommended to rely on the final list of varieties. In the recent market investment sentiment fluctuations in the pharmaceutical sector, considering that the sector's valuation was already at historically low levels, the bank believes there is still further room for recovery. Zhongtai Securities stated that looking ahead to the second half of the year, the full chain support for innovative drugs, equipment upgrades, the national essential drug list, and other advancements are expected to continue; medical insurance negotiations, major conferences in the innovative drug field such as ESMO/WCLC/ASH/American Academy of Ophthalmology annual meetings, GLP-1 research and development progress are expected to act as catalysts.

Editor/Rocky